Masanori Tsubosaka

Dr. Masanori Tsubosaka

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
MTMasanori Tsubosaka
Masanori Tsubosaka
HMHirotsugu Muratsu
Hirotsugu Muratsu
KTKoji Takayama
Koji Takayama
HMHidetoshi Miya
Hidetoshi Miya
RKRyosuke Kuroda
Ryosuke Kuroda
TMTomoyuki Matsumoto
Tomoyuki Matsumoto

1 November 2019 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
TKTomoyuki Kamenaga
Tomoyuki Kamenaga
Takafumi HiranakaTakafumi Hiranaka
Takafumi Hiranaka
KTKoji Takayama
Koji Takayama
MTMasanori Tsubosaka
Masanori Tsubosaka
RKRyosuke Kuroda
Ryosuke Kuroda
TMTomoyuki Matsumoto
Tomoyuki Matsumoto

1 January 2021 in Cell Transplantation
Verified
Journal Article
Open access
MTMasanori Tsubosaka
Masanori Tsubosaka
TMTomoyuki Matsumoto
Tomoyuki Matsumoto
SSSatoshi Sobajima
Satoshi Sobajima
TMTakehiko Matsushita
Takehiko Matsushita
HIHideki Iwaguro
Hideki Iwaguro
RKRyosuke Kuroda
Ryosuke Kuroda
Favorable clinical outcomes of intra-articular injection of adipose-derived stromal vascular fraction (SVF) cells for knee osteoarthritis (OA) have been reported, but the effects of different doses of SVF cells have not been examined. This study aimed to compare the short-term clinical and imaging outcomes of different doses of SVF cells for knee OA treatment. This study included 60 patients with knee OA who underwent intra-articular injection of SVF cells. The follow-up period was at least 12 months. Thirty patients received an intra-articular injection of 2.5×107 SVF cells (low-dose group), and the remaining 30 patients received an intra-articular injection of 5.0×107 SVF cells (high-dose group). Clinical evaluations were performed for the Knee injury and Osteoarthritis Outcome Score (KOOS). Imaging evaluations, including the magnetic resonance imaging Osteoarthritis Knee Score (MOAKS) features (bone marrow lesions, cartilage defects, osteophytes, Hoffa’s synovitis, and effusion synovitis), were also performed. All clinical and imaging evaluations were performed preoperatively and 12 months postoperatively and compared between the groups. In demographic data, no significant differences were found between the two groups. The total score of KOOS at 12 months postoperatively was significantly more favorable than the preoperative score in the high-dose groups. Pain and symptoms subscale scores of KOOS at 12 months postoperatively were significantly better in the high-dose group than in the low-dose group. The bone marrow lesions, Hoffa’s synovitis, and effusion synovitis improved approximately 30–40% at 12 months postoperatively compared to baseline in both groups. However, there were no significant differences in imaging evaluations between the two groups. In conclusion, the pain and symptoms subscale scores of KOOS from baseline to 12 months postoperatively improved better in the high-dose group than in the low-dose group. Our findings suggest that intra-articular injection of SVF cells for knee OA is an innovative approach.

10 January 2024 in Bone & Joint Research
Verified
Journal Article
Open access
PDF file
MTMasakazu Toya
Masakazu Toya
JKJunichi Kushioka
Junichi Kushioka
HSHuaishuang Shen
Huaishuang Shen
TUTakeshi Utsunomiya
Takeshi Utsunomiya
HHHIROHITO HIRATA
HIROHITO HIRATA
Stuart B GoodmanStuart B Goodman
Stuart B Goodman
Aims: Transcription factor nuclear factor kappa B (NF-κB) plays a major role in the pathogenesis of chronic inflammatory diseases in all organ systems. Despite its importance, NF-κB targeted drug therapy to mitigate chronic inflammation has had limited success in preclinical studies. We hypothesized that sex differences affect the response to NF-κB treatment during chronic inflammation in bone. This study investigated the therapeutic effects of NF-κB decoy oligodeoxynucleotides (ODN) during chronic inflammation in male and female mice.Methods: We used a murine model of chronic inflammation induced by continuous intramedullary delivery of lipopolysaccharide-contaminated polyethylene particles (cPE) using an osmotic pump. Specimens were evaluated using micro-CT and histomorphometric analyses. Sex-specific osteogenic and osteoclastic differentiation potentials were also investigated in vitro, including alkaline phosphatase, Alizarin Red, tartrate-resistant acid phosphatase staining, and gene expression using reverse transcription polymerase chain reaction (RT-PCR).Results: Local delivery of NF-κB decoy ODN in vivo increased osteogenesis in males, but not females, in the presence of chronic inflammation induced by cPE. Bone resorption activity was decreased in both sexes. In vitro osteogenic and osteoclastic differentiation assays during inflammatory conditions did not reveal differences among the groups. Receptor activator of nuclear factor kappa Β ligand (Rankl) gene expression by osteoblasts was significantly decreased only in males when treated with ODN.Conclusion: We demonstrated that NF-κB decoy ODN increased osteogenesis in male mice and decreased bone resorption activity in both sexes in preclinical models of chronic inflammation. NF-κB signalling could be a therapeutic target for chronic inflammatory diseases involving bone, especially in males.Cite this article: Bone Joint Res 2024;13(1):28–39.

5 January 2023 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
MTMasanori Tsubosaka
Masanori Tsubosaka
MMMasahiro Maruyama
Masahiro Maruyama
ELElaine Lui
Elaine Lui
SMSeyedsina Moeinzadeh
Seyedsina Moeinzadeh
EHElijah Ejun Huang
Elijah Ejun Huang
YYYunzhi Peter Yang
Yunzhi Peter Yang

12 March 2025 in Regenerative Therapy
Verified
Journal Article
Open access
TMTakuma Maeda
Takuma Maeda
SSSatoshi Sobajima
Satoshi Sobajima
TMTomoyuki Matsumoto
Tomoyuki Matsumoto
MTMasanori Tsubosaka
Masanori Tsubosaka
TMTakehiko Matsushita
Takehiko Matsushita
RKRyosuke Kuroda
Ryosuke Kuroda
Stromal vascular fraction (SVF) cells and micro-fragmented adipose tissue (MFAT) have potential for treating knee osteoarthritis (OA), but their efficacy has not been compared. This study aimed to compare the clinical outcomes of SVF and MFAT for knee OA. We hypothesized that SVF provides stronger short-term effects, while MFAT offers more sustained benefits. A retrospective single-center cohort study was conducted on patients with knee OA, with 36 SVF and 36 MFAT cases selected through propensity score matching between September 2017 and February 2022. Patients with KL grades I-IV varus knee OA, significant pain (VAS ≥40), and functional impairment despite conservative treatments were included. Those with knee trauma, severe bony defects, infections, genu valgus, osteonecrosis, rheumatoid arthritis, or severe deformities were excluded. Clinical outcomes were assessed using the visual analog scale, KOOS, knee range of motion, extension/flexion strength, and MRI T2 mapping. SVF and MFAT groups demonstrated significant improvements in VAS (p < 0.01 for both groups). Both groups showed notable improvements in extension angle, extension/flexion muscle strength, and KOOS, with no significant differences between them. However, the MFAT group demonstrated significantly greater improvement in flexion angle compared to the SVF group (p = 0.03). No serious adverse events were reported. T2 mapping showed significant improvements in cartilage quality in both groups, with the MFAT group demonstrating superior improvements in specific lateral regions. Responder rate in SVF group initially improved but declined over time; however, the MFAT group showed sustained improvement from six months onward. T2 mapping revealed that MFAT had better cartilage preservation than that of SVF cells in less-loaded areas, with a potentially longer-lasting therapeutic effect. These findings offer important insights for clinicians to tailor treatment strategies based on patient needs and disease progression.